Cytokine Hemoadsorption in ECMO Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Haemodynamic stabilization
研究概览
简要总结
Cytokine hemoadsorption is a novel therapy used to improve outcome in critically ill patients with a dysregulated cytokine response and hemodynamic instability. Patients on extracorporeal membraneous oxygenation (ECMO) often develop severe systemic inflammatory response syndrome (SIRS). Cytokine removal using different types of hemoadsorption devices is believed to block the vicious circle of inflammation dysregulation when other basic therapeutic measures fail. To date there are very limited reports on ECMO and cytokine hemoadsorption combination therapy. The aim of this retrospective study is to evaluate feasibility and effectiveness of hemoadsorption in veno-arterial and veno-venous ECMO patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •VA/VV ECMO
- •hemoadsorption
- •Age ≥ 18 years
排除标准
- •no additional exclusion criteria after being eligible for ECMO
结局指标
主要结局
Haemodynamic stabilization
时间窗: Within 12 hours after hemoadsorption
Decreased need for vasopressors according to vasoactive-inotropic score and increase in mean arterial pressure
次要结局
- Lactate, interleukin-6, C-reactive protein and procalcitonin clearance(Within 12 hours after hemoadsorption)
- ICU length of stay(from day of ICU-admission for every 24 hours until date of discharge or death, whichever came first, assessed up to 90 days)
- Weaning from ECMO(from day of ECMO-implant for every 24 hours until date of weaning or death, whichever came first, assessed up to 90 days)
- Hospital mortality(from day of hospital admission until date of discharge or death, whichever came first, assessed up to 90 days)
研究者
Jernej Berden
Jernej Berden, MD, PhD
University Medical Centre Ljubljana